Search results for "roe"

showing 10 items of 9822 documents

Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers

2021

BackgroundHypercalcemia is a common paraneoplastic syndrome which can occur in up to 10% of patients with advanced neoplasms. Paraneoplastic parathyroid hormone-related protein (PTHrP) represents the most frequent cause of this syndrome. In neuroendocrine neoplasms (NENs) paraneoplastic hypercalcemia is rare.Case SeriesThe present series includes all patients with NENs and paraneoplastic hypercalcemia from four Italian centres: (I) A 40-year-old man was hospitalized for repeated episodes of falls, hyposthenia and drowsiness. Severe hypercalcemia was found. Metastatic pancreatic G2 NEN and PTHrP-related hypercalcemia were diagnosed. The patient started therapy with somatostatin analogs (SSA)…

musculoskeletal diseasesAdultMalemedicine.medical_specialty125-dihydroxyvitamin Dbronchial carcinoidEndocrinology Diabetes and Metabolism1pancreatic NENCase ReportGastroenterologyDiseases of the endocrine glands. Clinical endocrinologyparaneoplastic hypercalcemia; parathyroid hormone-related protein; pancreatic nen; bronchial carcinoid; 125-dihydroxyvitamin dEndocrinologyparaneoplastic hypercalcemiaInternal medicinemedicineHumansVitamin DAgedEverolimusmedicine.diagnostic_testPerformance statusParathyroid hormone-related proteinbusiness.industryparathyroid hormone-related proteinMiddle AgedRC648-665PrognosisPancreatic NeoplasmsNeuroendocrine TumorsSomatostatinDenosumabPositron emission tomographyCalcitoninRadionuclide therapyHypercalcemiaFemalebusiness25-dihydroxyvitamin dhormones hormone substitutes and hormone antagonistsmedicine.drugFrontiers in Endocrinology
researchProduct

Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy.

2022

Abstract Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentEffectivenessYoung AdultInternal medicineAdalimumabMedicineHumansAdverse effectskin and connective tissue diseasesColectomyColectomyAgedRetrospective StudiesReal-world evidenceHepatologybusiness.industryGastroenterologyEffectiveneAdalimumabRetrospective cohort studyInduction ChemotherapyMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuationClinical PracticeTreatment OutcomeUlcerative colitisItalyAdalimumab; Effectiveness; Real-world evidence; Safety; Ulcerative colitisConcomitantColitis UlcerativeFemaleTumor Necrosis Factor InhibitorsSafetybusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Osteoprotegerin: a new biomarker for impaired bone metabolism in complex regional pain syndrome?

2014

Abstract Osteoprotegerin (OPG) is important for bone remodeling and may contribute to complex regional pain syndrome (CRPS) pathophysiology. We aimed to assess the value of OPG as a biomarker for CRPS and a possible correlation with radiotracer uptake in 3-phase bone scintigraphy (TPBS). OPG levels were analyzed in 23 CRPS patients (17 women; mean age 50 ± 9.0 years; disease duration: 12 weeks [IQR 8–24]), 10 controls (6 women; mean age 58 ± 9.6 years) and 21 patients after uncomplicated fractures (12 women; mean age: 43 ± 15 years; time after fracture: 15 weeks [IQR: 6–22]). The CRPS and control patients also underwent TPBS. OPG in CRPS patients was significantly increased by comparison wi…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyGastroenterologySensitivity and SpecificityBone remodeling03 medical and health sciences0302 clinical medicineOsteoprotegerinInternal medicinemedicineHumans030304 developmental biology0303 health sciencesmedicine.diagnostic_testReceiver operating characteristicbusiness.industryArea under the curveOsteoprotegerinMiddle Agedmedicine.diseasePathophysiologyBone Diseases MetabolicAnesthesiology and Pain MedicineEndocrinologyComplex regional pain syndromeNeurologyBone scintigraphyBiomarker (medicine)FemaleNeurology (clinical)business030217 neurology & neurosurgeryBiomarkersComplex Regional Pain SyndromesPainReferences
researchProduct

Dystroglycan regulates structure, proliferation and differentiation of neuroepithelial cells in the developing vertebrate CNS.

2007

AbstractIn the developing CNS α- and β-dystroglycan are highly concentrated in the endfeet of radial neuroepithelial cells at the contact site to the basal lamina. We show that injection of anti-dystroglycan Fab fragments, knockdown of dystroglycan using RNAi, and overexpression of a dominant-negative dystroglycan protein by microelectroporation in neuroepithelial cells of the chick retina and optic tectum in vivo leads to the loss of their radial morphology, to hyperproliferation, to an increased number of postmitotic neurons, and to an altered distribution of several basally concentrated proteins. Moreover, these treatments also altered the oriented growth of axons from retinal ganglion c…

musculoskeletal diseasesCentral Nervous Systemcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtySuperior Colliculianimal structuresCellular differentiationNeuroepithelial CellsStem cellsDevelopmentDystrophin-associated protein complexRetinal ganglionAxonal growthMuscular DystrophiesRetina03 medical and health sciences0302 clinical medicineInternal medicineDystroglycanmedicineAnimalsDystroglycansMolecular BiologyCell Shape030304 developmental biologyCell Proliferation0303 health sciencesRetinabiologyfungiCell DifferentiationCell BiologyMuscular dystrophymusculoskeletal systemCell biologyNeuroepithelial cellmedicine.anatomical_structureEndocrinologyRNAiVertebratesbiology.proteinBasal laminaPikachurinStem cellChickens030217 neurology & neurosurgeryDevelopmental BiologyDevelopmental biology
researchProduct

Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease.

2010

The treatment of moderate-to-severe steroid-dependent Crohn's disease has been a challenging issue for the gastroenterologist. Until to 10 years ago, immunosuppressors, mainly azathioprine or 6-mercaptopurine, were the best possible treatments available, and remission rates ranged from 30 to 60% according to the results of open studies and controlled trials. Recently, infliximab has been shown to be effective in steroid-dependent patients and, combined with azathioprine, it has been shown to increase 1-year remission rates. A recent large randomized controlled trial comparing infliximab, azathioprine and infliximab plus azathioprine demonstrated that the combination of infliximab plus azath…

musculoskeletal diseasesCrohn's diseasemedicine.medical_specialtySettore MED/09 - Medicina InternaHepatologyCombination therapybusiness.industryGastroenterologyAzathioprinemedicine.diseaseGastroenterologyInfliximablaw.inventionSurgeryRandomized controlled triallawInternal medicinemedicineInfliximab azathioprine Crohnbusinessmedicine.drug
researchProduct

Mechanical activity of small and large intestine in normal and mdx mice: a comparative analysis.

1999

The aim of this study was to compare the motor pattern (recorded as changes in intraluminal pressure) of isolated duodenum and proximal colon between dystrophic mdx and normal mice. When duodenal recordings from control preparations were compared with mdx mice there was no significant difference in the spontaneous motor pattern, responses to electrical nerve stimulation or sensitivity to pharmacological agents. Colonic segments from mdx mice showed a more complex motor pattern, consisting of contractions with amplitude and frequency similar to those of controls and by additional contractions with lower amplitude and higher frequency. Moreover, 70% of the colonic preparations from mdx mice d…

musculoskeletal diseasesMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyNerve stimulationPhysiologyColonDuodenumDuchenne muscular dystrophyIn Vitro TechniquesInhibitory postsynaptic potentialNitric oxidechemistry.chemical_compoundMiceReference ValuesInternal medicineIntestine SmallmedicineAnimalsLarge intestineProximal colonIntestine LargeEndocrine and Autonomic SystemsChemistrySignificant differenceGastroenterologyAnatomyMuscular Dystrophy Animalmusculoskeletal systemmedicine.diseaseElectric StimulationBiomechanical PhenomenaMice Inbred C57BLmedicine.anatomical_structureEndocrinologyDuodenumMice Inbred mdxGastrointestinal MotilityNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
researchProduct

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

2020

Introduction We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). Methods ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. Results Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. Discussion Once AIH has been ruled out, the long-term outcomes and survival are un…

musculoskeletal diseasesMalemedicine.medical_specialtyAntibodies Antinuclear; Biopsy; England; Female; Humans; Italy; Longitudinal Studies; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prevalence; Prospective Studies; Survival AnalysisAnti-nuclear antibodyBiopsySettore MED/12 - GASTROENTEROLOGIAAntibodies Antinuclear Biopsy EnglandFemale Humans Italy Longitudinal Studies Male Middle Aged Non-alcoholic Fatty Liver Disease Prevalence Prospective StudiesSurvival AnalysisAutoimmune hepatitisMalignancyGastroenterologyAntibodies03 medical and health sciences0302 clinical medicineimmune system diseasesNon-alcoholic Fatty Liver DiseaseInternal medicineAntinuclearBiopsyNonalcoholic fatty liver diseasemedicineCarcinomaPrevalenceHumansLongitudinal StudiesProspective Studiesskin and connective tissue diseasesProspective cohort studySurvival analysisHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseases3. Good healthstomatognathic diseasesn/aEnglandItaly030220 oncology & carcinogenesisAntibodies Antinuclear030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Arthralgia as an early extraintestinal symptom of Whipple's disease. Report of five cases.

1997

Five patients with Whipple's disease all suffered from arthralgia for a long time (15 years in one case) before developing gastrointestinal or other symptoms. In all patients, arthralgia was seronegative, and there was no evidence of joint destruction. Arthralgias were symmetric and migrating. Whipple's disease is part of the differential diagnosis of enteropathic arthralgia. Thereby, the polymerase chain reaction can be a helpful tool to prove Whipple's disease in difficult differential diagnosis.

musculoskeletal diseasesMalemedicine.medical_specialtyBiopsyDiagnostico diferencialDiseasePolymerase Chain ReactionIntestinal malabsorptionDiagnosis DifferentialBiopsymedicineHumansWhipple's diseaseskin and connective tissue diseasesmedicine.diagnostic_testJoint destructionBacteriabusiness.industryWhipple DiseaseGastroenterologyvirus diseasesMiddle Agedmedicine.diseaseDermatologyArthralgiadigestive system diseasesSurgerybody regionsDifferential diagnosisbusinessWhipple DiseaseJournal of clinical gastroenterology
researchProduct

Duodenal contractile activity in dystrophic (mdx) mice: reduction of nitric oxide influence.

2003

The present study was undertaken to analyse duodenal contractility in adult dystrophic (mdx) mice. The spontaneous changes of the isometric tension and the responses of longitudinal duodenal muscle to nonadrenergic, noncholinergic (NANC) nerve stimulation and to exogenous drugs were compared between normal and mdx mice. Duodenal segments from mdx mice displayed spontaneous contractions with higher frequency than normals. N omega-nitro-L-arginine methyl ester (L-NAME) increased the frequency of contractions in normals without affecting that in mdx mice. In normals, NANC nerve stimulation elicited a transient relaxation abolished by L-NAME. In mdx mice a frank relaxation was not observed, the…

musculoskeletal diseasesMalemedicine.medical_specialtyNerve stimulationPhysiologyDuodenumInhibitory pathwayIsometric exerciseIn Vitro TechniquesInhibitory postsynaptic potentialNitric OxideSettore BIO/09 - FisiologiaNitric oxideContractilityDystrophinchemistry.chemical_compoundMiceSmooth muscleInternal medicinemedicineSpontaneous contractionAnimalsNeuroscience (all)biologyDose-Response Relationship DrugEndocrine and Autonomic SystemsIntestinal relaxationGastroenterologymusculoskeletal systemMice Inbred C57BLEndocrinologychemistrybiology.proteinMice Inbred mdxmdx miceSodium nitroprussideDystrophinGastrointestinal Motilitytissuesmedicine.drugMuscle ContractionNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
researchProduct

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analy…

2018

Abstract Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in…

musculoskeletal diseasesModerate to severeAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaBiologicDisease durationAdalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies Monoclonal; Colitis Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alphaUlcerativeBiologicsGolimumabSeverity of Illness IndexTreatment failureAntibodies03 medical and health sciences0302 clinical medicineInternal medicineMonoclonalAdalimumabmedicineHumansskin and connective tissue diseasesAdalimumab; Biologics; Golimumab; Ulcerative colitis; Hepatology; GastroenterologyPropensity ScoreProportional Hazards ModelsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabAntibodies MonoclonalMiddle Agedmedicine.diseaseColitisUlcerative colitishumanitiesGolimumabLogistic ModelsTreatment OutcomeUlcerative colitisItaly030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessmedicine.drug
researchProduct